Arnica

Arnica sesquiterpene lactones inhibit NF-kB activation and reduce IL-12 and prostaglandin production through mechanisms complementary to NSAID COX inhibition. Topical arnica has been shown comparable to topical diclofenac for hand osteoarthritis. Oral arnica combined with oral NSAIDs may produce additive GI mucosa irritation and antiplatelet effects.

Topical arnica combined with topical NSAIDs is generally well-tolerated and may be beneficial. Avoid oral arnica with oral NSAIDs due to additive GI irritation and antiplatelet effects. In patients with GI ulcer history, this combination should be avoided.

Arnica sesquiterpene lactones (helenalin, dihydrohelenalin) inhibit platelet function via thiol-dependent pathways reducing phospholipase A2 activity. Arnica also contains coumarin derivatives (scopoletin, umbelliferone) that may directly contribute to anticoagulant activity. Italian Pharmacovigilance database documents 5 cases of INR increase in warfarin-treated patients who consumed arnica-based products.

Avoid oral arnica preparations in patients on anticoagulants. Even topical arnica can increase INR if systemic absorption occurs. Stop arnica use at least 2 weeks before elective surgery. If patient is using arnica, check INR promptly. Report any unusual bleeding. Topical arnica on intact skin carries low but non-zero risk.

Helenalin and dihydrohelenalin from Arnica montana inhibit platelet aggregation by interacting with platelet sulfhydryl groups, inhibiting phospholipase A2 and reducing thromboxane synthesis. These effects are additive with antiplatelet drugs that block P2Y12 receptors (clopidogrel, ticagrelor) or COX-1 (aspirin), significantly increasing bleeding risk.

Oral arnica is contraindicated with antiplatelet therapy. For topical arnica, caution is warranted. Discontinue oral arnica at least 2 weeks before surgery in patients on dual antiplatelet therapy. Monitor for bleeding signs. Advise patients undergoing cardiovascular procedures to avoid oral arnica products.

Arnica's antiplatelet effects (helenalin-mediated phospholipase A2 inhibition and thiol-dependent platelet inhibition) are additive with the platelet-inhibitory properties of sevoflurane and other volatile anesthetics. A case report describes massive bleeding from this combination. Perioperative bleeding is a serious surgical risk.

Stop all arnica preparations (oral and topical) at least 2 weeks before any surgery. Inform anesthesiologists and surgeons of arnica use. In emergency surgery where prior use is unknown, be prepared for potential excessive intraoperative bleeding. Monitor platelet function if feasible.

Arnica sesquiterpene lactones show immunomodulatory activity, suppressing NF-kB and IL-12 production in dendritic cells at high concentrations while having immunostimulatory effects at lower dilutions. This complex immunomodulation, combined with potential infection of compromised skin in immunosuppressed patients, requires caution.

Topical arnica use on intact skin for local pain/bruising in immunosuppressed patients is generally low risk. Oral arnica should be avoided. Monitor for skin infections at application sites in immunosuppressed individuals. Advise patients to report any skin changes.

Large doses of oral arnica can cause tachycardia, cardiac arrhythmias, and myocardial damage (arnica is classified as unsafe orally by the FDA in non-diluted forms). In patients taking digoxin or other cardiac medications, arnica-induced cardiac effects could destabilize cardiac rhythm or interact unpredictably with cardiac medications.

Oral non-diluted arnica is contraindicated in patients on cardiac medications. Homeopathic or highly diluted oral arnica preparations are unlikely to cause clinically significant effects. Topical preparations on intact skin are safe for cardiac patients. Warn patients against using arnica teas or tinctures with cardiac medications.